±êÌ⣺

ASPEN: Results of a Phase III Randomized Trial of Zanubrutinib Versus Ibrutinib for Patients with Waldenström Macroglobulinemia (WM)

ASPENÁÙ´²ÊÔÑ飺Ôó²¼ÌæÄá¶Ô±ÈÒÁ²¼ÌæÄáÓÃÓÚÖÎÁÆ»ªÊϾÞÇòµ°°×Ѫ֢£¨WM£©»¼ÕßµÄ3ÆÚËæ»úÁÙ´²ÊÔÑé½á¹û

ÕªÒª±àºÅ£º

8007

·Ö»á³¡±êÌ⣺

Hematologic Malignancies¡ªLymphoma and Chronic Lymphocytic Leukemia

ѪҺ¶ñÐÔÖ×Áö  ÁÜ°ÍÁö¼°ÂýÐÔÁÜ°Íϸ°û°×Ѫ²¡

µÚÒ»×÷Õߣº

Constantine S. Tam£¬ÄÚÍâÈ«¿Æҽѧʿ¡¢Ò½Ñ§²©Ê¿£¨°Ä´óÀûÑÇSt. VincentÒ½Ôº£©

±êÌâ

Three-Year Follow-up of Treatment-Naïve and Previously Treated Patients with Waldenström Macroglobulinemia (WM) Receiving Single-Agent Zanubrutinib

Ôó²¼ÌæÄáµ¥Ò©ÖÎÁƳõÖλò¼ÈÍù½ÓÊܹýÖÎÁƵĻªÊϾÞÇòµ°°×Ѫ֢£¨WM£©»¼ÕßµÄÈýÄêËæ·Ã½á¹û

ÕªÒª±àºÅ£º

8051

º£±¨±àºÅ£º

384

·Ö»á³¡±êÌ⣺

Hematologic Malignancies¡ªLymphoma and Chronic Lymphocytic Leukemia

ѪҺ¶ñÐÔÖ×Áö  ÁÜ°ÍÁö¼°ÂýÐÔÁÜ°Íϸ°û°×Ѫ²¡

µÚÒ»×÷Õߣº

Constantine S. Tam£¬ÄÚÍâÈ«¿Æҽѧʿ¡¢Ò½Ñ§²©Ê¿£¨°Ä´óÀûÑÇSt. VincentÒ½Ôº£©

±êÌ⣺

Phase 3 Study of Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First line (1L) Treatment for Advanced Squamous Non-Small Cell Lung Cancer (sq NSCLC)

°ÙÔó°²^®£¨ÌæÀ×ÀûÖéµ¥¿¹£©ÁªºÏ»¯ÁƶԱȽöÓû¯ÁÆÓÃÓÚÖÎÁÆÒ»ÏßÍíÆÚÁÛ×´·ÇСϸ°û·Î°©£¨NSCLC£©»¼ÕßµÄ3ÆÚÁÙ´²ÊÔÑé

ÕªÒª±àºÅ:

9554

º£±¨±àºÅ:

320

·Ö»á³¡±êÌ⣺

Lung Cancer¡ªNon-Small Cell Metastatic Poster Session

·Î°©  תÒÆÐÔ·ÇСϸ°û°©º£±¨Õ¹Ê¾·Ö»á³¡

µÚÒ»×÷Õߣº

Íõ½à£¬Ò½Ñ§²©Ê¿£¨Öйúҽѧ¿ÆѧԺÖ×ÁöÒ½Ôº£©

±êÌ⣺

Association Between Immune and Tumor Gene Signatures with Response or Resistance to Tislelizumab Monotherapy or in Combination with Chemotherapy in Gastroesophageal Adenocarcinoma

θʳ¹ÜÏÙ°©»¼Õß½ÓÊÜ°ÙÔó°²^®£¨ÌæÀ×ÀûÖéµ¥¿¹£©µ¥Ò©»òÁªºÏ»¯ÁÆÖÎÁƺó²úÉú»º½â»ò¿¹Ò©ÊÇ·ñÓëÃâÒß¼°Ö×Áö»ùÒòÌØÕ÷Ïà¹ØµÄÑо¿

ÕªÒª±àºÅ:

3115

º£±¨±àºÅ:

179

·Ö»á³¡±êÌ⣺

Developmental Therapeutics¡ªImmunotherapy Poster Session

Ñз¢½×¶ÎÁÆ·¨  ÃâÒßÖ×Áöº£±¨Õ¹Ê¾·Ö»á³¡

µÚÒ»×÷Õߣº

Ð콨Ã÷£¬Ò½Ñ§²©Ê¿£¨Öйú½â·Å¾ü×ÜÒ½Ôº£©